NOV

Analyst Sentiment

Wall St. Consensus
Hold
29 analysts·High coverage
59
Score
13 Buy (45%)14 Hold (48%)2 Sell (7%)
Rating Breakdown
Strong Buy
00%
Buy
1345%
Hold
1448%
Sell
27%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$15.00
-25.6%
Consensus
$19.50
-3.2%
Bull
$24.00
+19.1%
12-Month Target Range29 analysts
$15.00$19.50$24.00
Current $20.16Consensus
Current Price
$20.16
Above Consensus
$0.66

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+4.83%
EPS+52.48%
FY2028
Rev+3.62%
EPS+19.37%
FY2029
Rev+1.57%
EPS+11.25%

Earnings Surprises

Recent Analyst Actions

Apr 29, 2026Susquehanna
NOV Inc. price target raised to $24 from $22 at Susquehanna
Target:$24.00
+18.3%from $20.29
Apr 15, 2026Morgan Stanley
NOV Inc. price target raised to $20 from $18 at Morgan Stanley
Target:$20.00
+4.7%from $19.10
Feb 9, 2026Piper Sandler
NOV Inc. price target raised to $18 from $17 at Piper Sandler
Target:$18.00
-4.8%from $18.91
Feb 6, 2026Evercore ISI
NOV Inc. price target raised to $19 from $15 at Evercore ISI
Target:$19.00
+1.3%from $18.75
Feb 6, 2026Stifel Nicolaus
NOV Inc. price target raised to $21 from $19 at Stifel
Target:$21.00
+11.8%from $18.78
Feb 6, 2026Susquehanna
NOV Inc. price target raised to $21 from $20 at Susquehanna
Target:$21.00
+15.1%from $18.24
Jan 15, 2026RBC Capital
NOV Inc. price target raised to $21 from $19 at RBC Capital
Target:$21.00
+17.1%from $17.93
Jan 14, 2026Goldman Sachs
NOV Inc. price target raised to $17 from $14 at Goldman Sachs
Target:$17.00
-4.1%from $17.72
Jan 7, 2026Susquehanna
NOV Inc. price target raised to $20 from $17 at Susquehanna
Target:$20.00
+17.2%from $17.06
Dec 18, 2025Piper Sandler
NOV Inc. price target raised to $17 from $14 at Piper Sandler
Target:$17.00
+8.6%from $15.66
Dec 17, 2025Barclays
NOV Inc. price target raised to $15 from $13 at Barclays
Target:$15.00
-2.1%from $15.32
Dec 15, 2025Morgan Stanley
NOV Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Target:$16.00
-0.6%from $16.09
Nov 11, 2025Barclays
NOV Inc. price target lowered to $13 from $14 at Barclays
Target:$13.00
-16.9%from $15.64
Nov 5, 2025Goldman Sachs
NOV Inc. price target raised to $14 from $12 at Goldman Sachs
Target:$14.00
-5.9%from $14.88
Oct 30, 2025Barclays
NOV Inc. price target raised to $14 from $11 at Barclays
Target:$14.00
-8.6%from $15.31
Oct 29, 2025Stifel Nicolaus
NOV Inc. price target raised to $19 from $17 at Stifel
Target:$19.00
+25.2%from $15.18
Oct 29, 2025RBC Capital
NOV Inc. price target raised to $19 from $17 at RBC Capital
Target:$19.00
+25.5%from $15.14
Oct 28, 2025Raymond James
NOV Inc. (NOV) PT Raised to $17 at Raymond James
Target:$17.00
+13.7%from $14.95
Jul 30, 2025Susquehanna
NOV Inc. price target lowered to $17 from $18 at Susquehanna
Target:$17.00
+33.0%from $12.78
Apr 15, 2025Stifel Nicolaus
NOV Inc. price target lowered to $23 from $25 at Stifel
Target:$23.00
+91.5%from $12.01
Mar 24, 2025RBC Capital
NOV Inc. upgraded to Outperform from Sector Perform at RBC Capital
Target:$22.00
+45.5%from $15.12
Dec 18, 2024Barclays
NOV Inc. price target lowered to $12 from $16 at Barclays
Target:$12.00
-15.4%from $14.19
Oct 11, 2024Stifel Nicolaus
NOV Inc. price target lowered to $25 from $26 at Stifel
Target:$25.00
+53.8%from $16.25
Oct 10, 2024BMO Capital
NOV Inc. price target lowered to $20 from $22 at BMO Capital
Target:$20.00
+25.5%from $15.93
Sep 16, 2024Morgan Stanley
NOV Inc. price target lowered to $23 from $25 at Morgan Stanley
Target:$23.00
+45.0%from $15.86